Related Experiment Video
Updated: Dec 30, 2025
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
Published on: April 18, 2025
Modeling of Effective Antimicrobials to Reduce Staphylococcus aureus Virulence Gene Expression Using a
Sanjay K Shukla1, Tonia C Carter1, Zhan Ye1
1Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI 54449, USA.
Abstract:
Toxins produced by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) contribute to virulence. We developed a statistical approach to determine an optimum sequence of antimicrobials to treat CA-MRSA infections based on an antimicrobial's ability to reduce virulence. In an in vitro pharmacodynamic hollow fiber model, expression of six virulence genes (lukSF-PV, sek, seq, ssl8, ear, and lpl10) in CA-MRSA USA300 was measured by RT-PCR at six time points with or without human-simulated, pharmacokinetic dosing of five antimicrobials (clindamycin, minocycline, vancomycin, linezolid, and trimethoprim/sulfamethoxazole (SXT)). Statistical modeling identified the antimicrobial causing the greatest decrease in virulence gene expression at each time-point. The optimum sequence was SXT at T0 and T4, linezolid at T8, and clindamycin at T24-T72 when lukSF-PV was weighted as the most important gene or when all six genes were weighted equally. This changed to SXT at T0-T24, linezolid at T48, and clindamycin at T72 when lukSF-PV was weighted as unimportant. The empirical p-value for each optimum sequence according to the different weights was 0.001, 0.0009, and 0.0018 with 10,000 permutations, respectively, indicating statistical significance. A statistical method integrating data on change in gene expression upon multiple antimicrobial exposures is a promising tool for identifying a sequence of antimicrobials that is effective in sustaining reduced CA-MRSA virulence.
Insights
This study developed a statistical method to find the best antimicrobial sequence for treating community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections by reducing virulence gene expression. The optimal sequence varied based on gene weighting, showing promise for sustained CA-MRSA virulence reduction.
Area of Science:
- Microbiology
- Pharmacology
- Statistical Modeling
Background:
- Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections pose a significant threat due to toxins contributing to virulence.
- Effective treatment strategies for CA-MRSA require targeting virulence factors alongside bacterial load reduction.
Purpose of the Study:
- To develop and validate a statistical approach for determining an optimal antimicrobial sequence to reduce CA-MRSA virulence.
- To identify specific antimicrobial sequences that effectively suppress key virulence genes in CA-MRSA.
Main Methods:
- Utilized an in vitro pharmacodynamic hollow fiber model with CA-MRSA USA300.
- Measured expression of six critical virulence genes (lukSF-PV, sek, seq, ssl8, ear, lpl10) using RT-PCR.
- Applied statistical modeling to pharmacokinetic dosing of five antimicrobials (clindamycin, minocycline, vancomycin, linezolid, SXT) to identify optimal sequences based on virulence gene reduction.
Main Results:
- Statistical modeling identified distinct optimal antimicrobial sequences (SXT, linezolid, clindamycin) depending on the weighting of virulence genes, particularly lukSF-PV.
- Sequences demonstrated statistically significant reductions in virulence gene expression (empirical p-values < 0.002).
- The optimal sequence varied based on whether lukSF-PV was weighted as most important or unimportant.
Conclusions:
- A novel statistical method integrating gene expression data from multiple antimicrobial exposures can guide the selection of effective antimicrobial sequences.
- This approach holds promise for developing treatment strategies that sustain reduced virulence in CA-MRSA infections.
- Optimizing antimicrobial sequencing based on virulence reduction offers a new paradigm for combating challenging bacterial infections.
